Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

11/12/24 4:26:14 PM ET

$ELEV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELEV alert in real time by email

SC 13G/A 1 ea0220923-13ga3aisling4_elev.htm AMENDMENT NO. 3 TO SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

Elevation Oncology, Inc.
(Name of Issuer)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

28623U101
(CUSIP Number)

September 30, 2024
(Date of Event Which Requires Filing of this Statement)

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

☐	Rule 13d-1(b)

☐	Rule 13d-1(c)

☒	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons Aisling Capital IV, LP
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned By Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,913,005
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,913,005

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,913,005 ⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 4.92% ⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1)	Represents (i) 2,834,910 shares of Common Stock and (ii) 78,095 shares of Common Stock issuable in respect of 78,095 Stock Options beneficially owned by the Reporting Person.

(2)	Calculated based on 59,119,055 shares of Common Stock outstanding as of November 1, 2024 as reported on the Issuer’s Form 10-Q, filed on November 6, 2024, as increased by 78,095 shares of Common Stock issuable upon exercise of 78,095 Stock Options.

1.	Names of Reporting Persons Aisling Capital Partners IV LLC
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares
Beneficially Owned
By Each Reporting
Person With

Sole Voting Power

Shared Voting Power

2,913,005

Sole Dispositive Power

Shared Dispositive Power

2,913,005

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,913,005 ⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 4.92% ⁽²⁾
12.	Type of Reporting Person (See Instructions) OO

(1)	Represents (i) 2,834,910 shares of Common Stock and (ii) 78,095 shares of Common Stock issuable in respect of 78,095 Stock Options beneficially owned by the Reporting Person.

(2)	Calculated based on 59,119,055 shares of Common Stock outstanding as of November 1, 2024 as reported on the Issuer’s Form 10-Q, filed on November 6, 2024, as increased by 78,095 shares of Common Stock issuable upon exercise of 78,095 Stock Options.

1.	Names of Reporting Persons Aisling Capital Partners IV, LP
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned By Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,913,005
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,913,005

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,913,005 ⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 4.92% ⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1)	Represents (i) 2,834,910 shares of Common Stock and (ii) 78,095 shares of Common Stock issuable in respect of 78,095 Stock Options beneficially owned by the Reporting Person.

(2)	Calculated based on 59,119,055 shares of Common Stock outstanding as of November 1, 2024 as reported on the Issuer’s Form 10-Q, filed on November 6, 2024, as increased by 78,095 shares of Common Stock issuable upon exercise of 78,095 Stock Options.

1.	Names of Reporting Persons Steve Elms
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization USA

Number of Shares Beneficially Owned By Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,913,005
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,913,005

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,913,005 ⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 4.92% ⁽²⁾
12.	Type of Reporting Person (See Instructions) IN

(1)	Represents (i) 2,834,910 shares of Common Stock and (ii) 78,095 shares of Common Stock issuable in respect of 78,095 Stock Options beneficially owned by the Reporting Person.

(2)	Calculated based on 59,119,055 shares of Common Stock outstanding as of November 1, 2024 as reported on the Issuer’s Form 10-Q, filed on November 6, 2024, as increased by 78,095 shares of Common Stock issuable upon exercise of 78,095 Stock Options.

1.	Names of Reporting Persons Andrew N. Schiff
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization USA

Number of Shares Beneficially Owned By Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,913,005
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,913,005

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,913,005 ⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 4.92% ⁽²⁾
12.	Type of Reporting Person (See Instructions) IN

(1)	Represents (i) 2,834,910 shares of Common Stock and (ii) 78,095 shares of Common Stock issuable in respect of 78,095 Stock Options beneficially owned by the Reporting Person.

(2)	Calculated based on 59,119,055 shares of Common Stock outstanding as of November 1, 2024 as reported on the Issuer’s Form 10-Q, filed on November 6, 2024, as increased by 78,095 shares of Common Stock issuable upon exercise of 78,095 Stock Options.

Item 1(a).

Name of Issuer:

Elevation Oncology, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

101 Federal Street, Suite 1900

Boston, Massachusetts 02110

Item 2(a).

Names of Persons Filing:

This statement is filed by the entities and persons listed below, each of whom is referred to herein as a “Reporting Person” and together as the “Reporting Persons”:

1. Aisling Capital IV, LP (“Aisling Fund IV”)

2. Aisling Capital Partners IV, LP (“Aisling GP”)

3. Aisling Capital Partners IV LLC (“Aisling LLC”)

4. Steve Elms

5. Andrew N. Schiff

Item 2(b).

Address of the Principal Business Office or, if None, Residence:

C/O Aisling Capital Management LP

489 5th Ave., 10th Floor

New York, NY 10017

Item 2(c).

Citizenship:

See responses to Item 4 on each cover page.

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 per share

Item 2(e).

CUSIP Number:

28623U101

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

Not Applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

See response to Item 9 on each cover page.

(b)

Percent of Class:

See response to Item 11 on each cover page.

(c)

Number of shares as to which the Reporting Person has:

Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

The shares of Common Stock are directly held by Aisling Capital IV, LP (“Aisling Fund IV”) and the Stock Options are directly held by Steve Elms for the benefit of Aisling. Aisling Capital Partners IV, LP (“Aisling GP”), is the general partner of Aisling Fund IV, and Aisling Capital Partners IV LLC (“Aisling LLC”), is the general partner of Aisling GP. The managers of Aisling LLC are Dr. Andrew Schiff and Steve Elms, who share voting power and dispositive powers over securities held by Aisling, and as a result, may each be deemed to have beneficial ownership over such securities. This Statement shall not be construed as an admission that any of the Reporting Persons are, for purposes of Section 13(d) and 13(g), beneficial owners of the reported securities.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certification.

Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 12, 2024

	Aisling Capital IV, LP

	By:	/s/ Andrew Schiff
	Name:	Andrew Schiff
	Title:	Managing Member

	Aisling Capital Partners IV, LP

	By:	/s/ Andrew Schiff
	Name:	Andrew Schiff
	Title:	Managing Member

	Aisling Capital Partners IV LLC

	By:	/s/ Andrew Schiff
	Name:	Andrew Schiff
	Title:	Managing Member

	Andrew Schiff

	By:	/s/ Andrew Schiff
	Name:	Andrew Schiff

	Steve Elms

	By:	/s/ Steve Elms
	Name:	Steve Elms

EXHIBIT LIST

Exhibit A

Joint Filing Agreement, dated as of February 14, 2022, incorporated by reference to the Reporting Persons’ 13G, filed on February 14, 2022.

Get the next $ELEV alert in real time by email

Date	Price Target	Rating	Analyst
5/31/2024	$10.00	Overweight	Piper Sandler
5/14/2024	$8.00	Overweight	Stephens
3/1/2024	$7.00	Mkt Outperform	JMP Securities
5/30/2023	$5.00 → $8.00	Market Perform → Outperform	SVB Securities
3/4/2022	$27.00 → $21.00	Outperform	Wedbush
12/23/2021	$12.00	Buy	HC Wainwright & Co.
7/20/2021	$24.00	Overweight	JP Morgan
7/20/2021	$27.00	Outperform	Wedbush

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Chat with this insight

Recent Analyst Ratings for $ELEV

$ELEV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on Elevation Oncology with a new price target

Stephens initiated coverage on Elevation Oncology with a new price target

JMP Securities initiated coverage on Elevation Oncology with a new price target

$ELEV Large Ownership Changes

This live feed shows all institutional transactions in real time.